These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 33058542)
1. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status. Li HN; Li XR; Lv ZT; Cai MM; Wang G; Yang ZF Cancer Med; 2020 Dec; 9(24):9554-9570. PubMed ID: 33058542 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes. Kim HM; Koo JS Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580398 [TBL] [Abstract][Full Text] [Related]
3. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer. Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441 [TBL] [Abstract][Full Text] [Related]
4. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer. Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497 [TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453 [TBL] [Abstract][Full Text] [Related]
6. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033 [TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037 [TBL] [Abstract][Full Text] [Related]
8. Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype. Zanardi E; Di Meglio A; Boccardo C; Zinoli L; Salvi S; Rubagotti A Oncol Res Treat; 2020; 43(7-8):362-371. PubMed ID: 32512573 [TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251 [TBL] [Abstract][Full Text] [Related]
10. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases]. Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Expressions of Senescence-Associated Secretory Phenotype and Its Association With Immune Microenvironments and Clinicopathological Factors in Invasive Breast Cancer. Park MH; Choi JE; Kim JR; Bae YK Pathol Oncol Res; 2021; 27():1609795. PubMed ID: 34267603 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in Uchida S; Kojima T; Sugino T Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600 [TBL] [Abstract][Full Text] [Related]
13. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis. Ramezani F; Salami S; Omrani MD; Maleki D Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805 [TBL] [Abstract][Full Text] [Related]
14. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Waks AG; Stover DG; Guerriero JL; Dillon D; Barry WT; Gjini E; Hartl C; Lo W; Savoie J; Brock J; Wesolowski R; Li Z; Damicis A; Philips AV; Wu Y; Yang F; Sullivan A; Danaher P; Brauer HA; Osmani W; Lipschitz M; Hoadley KA; Goldberg M; Perou CM; Rodig S; Winer EP; Krop IE; Mittendorf EA; Tolaney SM Clin Cancer Res; 2019 Aug; 25(15):4644-4655. PubMed ID: 31061067 [TBL] [Abstract][Full Text] [Related]
15. lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer. Zhang Y; Li Z; Chen M; Chen H; Zhong Q; Liang L; Li B Breast Cancer; 2020 Jul; 27(4):573-585. PubMed ID: 31960363 [TBL] [Abstract][Full Text] [Related]
16. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration. Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588 [TBL] [Abstract][Full Text] [Related]
17. ERα-36 regulates progesterone receptor activity in breast cancer. Konan HP; Kassem L; Omarjee S; Surmieliova-Garnès A; Jacquemetton J; Cascales E; Rezza A; Trédan O; Treilleux I; Poulard C; Le Romancer M Breast Cancer Res; 2020 May; 22(1):50. PubMed ID: 32429997 [TBL] [Abstract][Full Text] [Related]
18. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis. Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532 [TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. Wu JR; Zhao Y; Zhou XP; Qin X Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575 [TBL] [Abstract][Full Text] [Related]
20. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Lee HJ; Song IH; Park IA; Heo SH; Kim YA; Ahn JH; Gong G Oncotarget; 2016 May; 7(21):30119-32. PubMed ID: 27121061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]